BeOne Medicines AG ONC
As ofNov 20, 2026, 12:19 PM EST
- YTD
- +30.13%
- 1 year
- +13.19%
5D -20.77 (-4.97%)
- Market cap
- 45.14B
- Revenue (ttm)
- 6.61B
- Profit margin
- 13.86%
- EPS (ttm)
- 7.80
- Shares out
- 105.38M
- P/E ratio
- 50.66
- Forward P/E
- 37.07
- YTD return
- +30.13%
- 1-year return
- +13.19%
- 50-day average
- 372.52
- Volume
- 193.24K
- Avg volume
- 391.11K
- Open
- 386.44
- Previous close
- 399.70
- Day's range
- 385.00 – 399.76
- 52-week range
- 253.95 – 424.73
- Beta
- 0.63
- Analysts
- Strong Buy
- Price target
- 470.52 (+19.0%)
- Earnings date
- Feb 25, 2027
Key statistics
- 200-day average
- 328.78
- Enterprise value
- 42.38B
- PEG ratio
- 0.71
- Price / sales
- 6.91
- Price / book
- 7.84
- Revenue growth
- 33.80%
- Free cash flow
- 1.03B
- Total cash
- 5.78B
- Total debt
- 2.06B
- Return on equity
- 18.40%
- Short % of float
- 1.97%
Fundamental scorecard
15 of 25 checks passed on ONC’s reported financials
15of 25 checks passed
- Value 1 of 5
- Growth 5 of 5
- Profitability 4 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 412.00
- Target (mean)
- 470.52
- Target (high)
- 561.30
- Strong buy7
- Buy19
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 2.65.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 3.99 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 2.34 | 4.59 | +2.25 | +96.15% |
| Aug 5, 2026 | Jun 30, 2026 | 1.63 | 2.05 | +0.42 | +25.77% |
| May 6, 2026 | Mar 31, 2026 | 0.73 | 1.96 | +1.23 | +168.49% |
| Feb 26, 2026 | Dec 31, 2025 | 1.60 | 0.58 | -1.02 | -63.75% |
| Nov 6, 2025 | Sep 30, 2025 | 0.72 | 1.09 | +0.37 | +51.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 6, 2026 | Truist Securities | reit | Buy | Buy |
| Nov 6, 2026 | Barclays | main | Overweight | Overweight |
| Nov 6, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Nov 6, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- beonemedicines.com
News
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $460
If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today BeOne Medicines Partners With CLL Society To Expand Support For Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Resources
CLL Society and BeOne Medicines Announce Expanded Partnership to Advance Education and Support Across the CLL/SLL Community Morgan Stanley Maintains Overweight on BeOne Medicines, Raises Price Target to $476
12 Health Care Stocks Moving In Friday's After-Market Session RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465
Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $463
Your note
Sign in to keep a note on ONC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Unknown | Sale | Dec 8, 2024 | 0 |
| BAKER BROTHERS LIFE SCIENCES, L.P. | Unknown | Sale | Feb 27, 2025 | 0 |
| BALL TITUS BENJAMIN | Officer | Sale | Nov 5, 2026 | 0 |
| DUGAN MARGARET | Director | Sale | May 21, 2026 | 0 |
| LEE CHAN HENRY | General Counsel | Sale | Nov 4, 2026 | 0 |
| RIVA ALESSANDRO | Director | Sale | May 21, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 8.04% | 8,832,335 | 3.53B | Sep 29, 2026 |
| Primecap Management Company | 4.47% | 4,906,701 | 1.96B | Sep 29, 2026 |
| Capital International Investors | 4.20% | 4,608,909 | 1.84B | Sep 29, 2026 |
| Capital World Investors | 3.55% | 3,902,319 | 1.56B | Sep 29, 2026 |
| FMR, LLC | 2.11% | 2,321,959 | 928.09M | Sep 29, 2026 |
| Blackrock Inc. | 0.73% | 804,086 | 321.39M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEW PERSPECTIVE FUND | 2.76% | 3,035,500 | 1.21B | Sep 29, 2026 |
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 2.14% | 2,347,622 | 938.34M | Jun 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 1.08% | 1,182,071 | 472.47M | Jun 29, 2026 |
| New Economy Fund | 0.89% | 972,969 | 388.90M | Sep 29, 2026 |
| AMERICAN FUNDS FUNDAMENTAL INVESTORS | 0.74% | 808,969 | 323.34M | Sep 29, 2026 |
| New World Fund Inc | 0.65% | 710,365 | 283.93M | Sep 29, 2026 |
